Maxim Group Reaffirms Hold Rating for Cytori Therapeutics (CYTX)

Maxim Group reissued their hold rating on shares of Cytori Therapeutics (NASDAQ:CYTX) in a research note issued to investors on Monday morning.

CYTX has been the topic of a number of other research reports. ValuEngine raised Cytori Therapeutics from a hold rating to a buy rating in a research report on Tuesday, September 4th. Zacks Investment Research lowered Cytori Therapeutics from a buy rating to a hold rating in a research report on Tuesday, October 16th. Finally, HC Wainwright dropped their price target on Cytori Therapeutics from $6.00 to $5.00 and set a buy rating on the stock in a research report on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Cytori Therapeutics currently has a consensus rating of Buy and an average price target of $10.56.

NASDAQ:CYTX opened at $0.33 on Monday. Cytori Therapeutics has a 1-year low of $0.29 and a 1-year high of $5.40.

Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Wednesday, November 14th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.29). The company had revenue of $1.31 million during the quarter, compared to analyst estimates of $3.24 million. Cytori Therapeutics had a negative net margin of 366.48% and a negative return on equity of 202.61%. During the same period in the previous year, the company posted ($1.40) EPS. As a group, equities analysts anticipate that Cytori Therapeutics will post -0.99 EPS for the current year.

About Cytori Therapeutics

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

Featured Article: How can investors find ex-dividend dates?

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply